$ICU
SeaStar Medical Holding Corp

2024 Q4 Form 10-Q Financial Statement

#000095017024126498 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q4
Revenue $68.00K $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $68.00K
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin $1.868M
YoY Change -62.79%
% of Gross Profit
Research & Development $2.336M $1.075M
YoY Change 111.02% -14.68%
% of Gross Profit 3435.29%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.524M $2.943M
YoY Change 54.09% -61.88%
Operating Profit -$4.456M
YoY Change 51.77%
Interest Expense $272.0K -$959.0K
YoY Change 21.43% -27.89%
% of Operating Profit
Other Income/Expense, Net -$22.00K -$5.978M
YoY Change -99.51% -41.22%
Pretax Income -$4.478M -$9.880M
YoY Change -39.7% -48.6%
Income Tax $0.00 -$5.000K
% Of Pretax Income
Net Earnings -$4.478M -$9.875M
YoY Change -39.7% -48.62%
Net Earnings / Revenue -6585.29%
Basic Earnings Per Share -$1.10
Diluted Earnings Per Share -$1.10 -$0.26
COMMON SHARES
Basic Shares Outstanding 4.463M 4.169M 36.98M
Diluted Shares Outstanding 4.087M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $176.0K
YoY Change 252.0%
Cash & Equivalents $2.082M $176.0K
Short-Term Investments
Other Short-Term Assets $2.132M
YoY Change -28.46%
Inventory $0.00
Prepaid Expenses $1.466M $2.132M
Receivables $68.00K $0.00
Other Receivables $0.00
Total Short-Term Assets $3.616M $2.308M
YoY Change 61.07% -23.98%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.205M
YoY Change -30.35%
Total Long-Term Assets $970.0K $1.205M
YoY Change 48400.0% -30.39%
TOTAL ASSETS
Total Short-Term Assets $3.616M $2.308M
Total Long-Term Assets $970.0K $1.205M
Total Assets $4.586M $3.513M
YoY Change 104.09% -26.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.687M $4.372M
YoY Change -26.87% 126.88%
Accrued Expenses $2.291M $1.523M
YoY Change 54.69% -32.16%
Deferred Revenue $550.0K $0.00
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $4.744M
YoY Change 302.72%
Total Short-Term Liabilities $6.638M $13.05M
YoY Change -46.59% 143.85%
LONG-TERM LIABILITIES
Long-Term Debt $4.337M
YoY Change -43.31%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $4.337M
YoY Change -43.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.638M $13.05M
Total Long-Term Liabilities $4.337M
Total Liabilities $6.638M $17.38M
YoY Change -63.43% 33.69%
SHAREHOLDERS EQUITY
Retained Earnings -$135.1M -$114.7M
YoY Change 16.79% 15.48%
Common Stock $1.000K $5.000K
YoY Change -66.67% 400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.052M -$13.87M
YoY Change
Total Liabilities & Shareholders Equity $4.586M $3.513M
YoY Change 104.09% -26.31%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q4
OPERATING ACTIVITIES
Net Income -$4.478M -$9.875M
YoY Change -39.7% -48.62%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.485M
YoY Change -15.38%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.588M
YoY Change -13.43%
NET CHANGE
Cash From Operating Activities -4.485M
Cash From Investing Activities
Cash From Financing Activities 4.588M
Net Change In Cash 103.0K
YoY Change 11059540787199900.0%
FREE CASH FLOW
Cash From Operating Activities -$4.485M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001831868
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39927
dei Entity Registrant Name
EntityRegistrantName
SEASTAR MEDICAL HOLDING CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3681132
dei Entity Address Address Line1
EntityAddressAddressLine1
3513 Brighton Blvd.,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 410
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80216
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
427-8100
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4463148
CY2024Q3 us-gaap Cash
Cash
2082000
CY2023Q4 us-gaap Cash
Cash
176000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
68000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1466000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2132000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
3616000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2308000
CY2024Q3 us-gaap Other Assets
OtherAssets
970000
CY2023Q4 us-gaap Other Assets
OtherAssets
1205000
CY2024Q3 us-gaap Assets
Assets
4586000
CY2023Q4 us-gaap Assets
Assets
3513000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3687000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4372000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2291000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1523000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
550000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
100000
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
565000
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
4179000
CY2024Q3 icu Liability Classified Warrants
LiabilityClassifiedWarrants
110000
CY2023Q4 icu Liability Classified Warrants
LiabilityClassifiedWarrants
2307000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6638000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13046000
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
4143000
CY2024Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
194000
CY2024Q3 us-gaap Liabilities
Liabilities
6638000
CY2023Q4 us-gaap Liabilities
Liabilities
17383000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4214399
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4214399
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2016045
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2016045
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
133092000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
100863000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135145000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114734000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-2052000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13870000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4586000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3513000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
CY2024Q3 us-gaap Gross Profit
GrossProfit
68000
us-gaap Gross Profit
GrossProfit
68000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2336000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1087000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6367000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4798000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2188000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1855000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6776000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6475000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4524000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2942000
us-gaap Operating Expenses
OperatingExpenses
13143000
us-gaap Operating Expenses
OperatingExpenses
11273000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4456000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2942000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13075000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11273000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
58000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
0
us-gaap Investment Income Interest
InvestmentIncomeInterest
82000
us-gaap Investment Income Interest
InvestmentIncomeInterest
0
CY2024Q3 us-gaap Interest Expense
InterestExpense
272000
CY2023Q3 us-gaap Interest Expense
InterestExpense
224000
us-gaap Interest Expense
InterestExpense
497000
us-gaap Interest Expense
InterestExpense
882000
CY2024Q3 icu Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
0
CY2023Q3 icu Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-291000
icu Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-6145000
icu Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-291000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-192000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1025000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
773000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1784000
CY2024Q3 icu Change In Fair Value Of Forward Option Prepaid Forward Contracts
ChangeInFairValueOfForwardOptionPrepaidForwardContracts
0
CY2023Q3 icu Change In Fair Value Of Forward Option Prepaid Forward Contracts
ChangeInFairValueOfForwardOptionPrepaidForwardContracts
0
icu Change In Fair Value Of Forward Option Prepaid Forward Contracts
ChangeInFairValueOfForwardOptionPrepaidForwardContracts
0
icu Change In Fair Value Of Forward Option Prepaid Forward Contracts
ChangeInFairValueOfForwardOptionPrepaidForwardContracts
1308000
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4949000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4949000
CY2024Q3 us-gaap Other Income
OtherIncome
0
CY2023Q3 us-gaap Other Income
OtherIncome
149000
us-gaap Other Income
OtherIncome
0
us-gaap Other Income
OtherIncome
149000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4290000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7333000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5497000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4478000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7232000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20408000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16770000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-4478000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-7232000
us-gaap Profit Loss
ProfitLoss
-20411000
us-gaap Profit Loss
ProfitLoss
-16775000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.1
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.1
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.1
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-26.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-26.16
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4086871
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4086871
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
801939
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
801939
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3348490
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3348490
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
641125
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
641125
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13870000
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
9389000
CY2024Q1 icu Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
3959000
CY2024Q1 icu Stock Issued During Period Value Equity Offering
StockIssuedDuringPeriodValueEquityOffering
8309000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
434000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-12697000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4476000
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
826000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
56000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3236000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6901000
CY2024Q3 icu Stock Issued During Period Value Equity Offering
StockIssuedDuringPeriodValueEquityOffering
8917000
CY2024Q3 icu Stock Issued During Period Value Board Compensation
StockIssuedDuringPeriodValueBoardCompensation
210000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
200000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4478000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-2052000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-20762000
CY2023Q1 icu Stock Issued During Period Value Equity Line Of Credit
StockIssuedDuringPeriodValueEquityLineOfCredit
1108000
CY2023Q1 icu Stock Issued During Period Value Commitment Fee For Equity Line
StockIssuedDuringPeriodValueCommitmentFeeForEquityLine
1000000
CY2023Q1 icu Stock Issued During Period Value Prepaid Forward Contracts
StockIssuedDuringPeriodValuePrepaidForwardContracts
1870000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
505000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7096000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-23375000
CY2023Q2 icu Stock Issued During Period Value Equity Line Of Credit
StockIssuedDuringPeriodValueEquityLineOfCredit
55000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1937000
CY2023Q2 icu Forward Purchase Agreement Derivative Liabilities
ForwardPurchaseAgreementDerivativeLiabilities
11519000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
555000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2447000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-11756000
CY2023Q3 icu Stock Issued During Period Value Equity Line Of Credit
StockIssuedDuringPeriodValueEquityLineOfCredit
120000
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2411000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
440000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7232000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-16017000
us-gaap Profit Loss
ProfitLoss
-20411000
us-gaap Profit Loss
ProfitLoss
-16775000
icu Amortization Of Deferred Financing Costs
AmortizationOfDeferredFinancingCosts
102000
icu Amortization Of Deferred Financing Costs
AmortizationOfDeferredFinancingCosts
37000
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
-6145000
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
-291000
icu Change In Fair Value Of Forward Purchase Agreement Derivative Liability
ChangeInFairValueOfForwardPurchaseAgreementDerivativeLiability
0
icu Change In Fair Value Of Forward Purchase Agreement Derivative Liability
ChangeInFairValueOfForwardPurchaseAgreementDerivativeLiability
1308000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
773000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1784000
us-gaap Share Based Compensation
ShareBasedCompensation
675000
us-gaap Share Based Compensation
ShareBasedCompensation
1544000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4949000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
68000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-12000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-666000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-805000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-235000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-858000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3115000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
932000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
698000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
495000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11314000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5800000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
979000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
6500000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
700000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
282000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13582000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1283000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
853000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
icu Issuance Of Pre Funded Warrants
IssuanceOfPreFundedWarrants
3766000
icu Issuance Of Pre Funded Warrants
IssuanceOfPreFundedWarrants
0
icu Payment Of Commitment Fee Equity Line Of Credit
PaymentOfCommitmentFeeEquityLineOfCredit
0
icu Payment Of Commitment Fee Equity Line Of Credit
PaymentOfCommitmentFeeEquityLineOfCredit
500000
icu Proceeds From Sale Of Recycled Shares
ProceedsFromSaleOfRecycledShares
0
icu Proceeds From Sale Of Recycled Shares
ProceedsFromSaleOfRecycledShares
1870000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
100000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5260000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3145000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13220000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5826000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1906000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
26000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
176000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2082000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73000
us-gaap Interest Paid Net
InterestPaidNet
523000
us-gaap Interest Paid Net
InterestPaidNet
707000
icu Exercise Of Liability Classified Warrants
ExerciseOfLiabilityClassifiedWarrants
3106000
icu Exercise Of Liability Classified Warrants
ExerciseOfLiabilityClassifiedWarrants
0
icu Shares Issued As Payment Of Convertible Notes
SharesIssuedAsPaymentOfConvertibleNotes
10210000
icu Shares Issued As Payment Of Convertible Notes
SharesIssuedAsPaymentOfConvertibleNotes
4348000
icu Shares Issued To Settle Forward Option Prepaid Forward Contracts
SharesIssuedToSettleForwardOptionPrepaidForwardContracts
0
icu Shares Issued To Settle Forward Option Prepaid Forward Contracts
SharesIssuedToSettleForwardOptionPrepaidForwardContracts
558000
icu Board Compensation Settled In Shares Of Common Stock In Lieu Of Cash
BoardCompensationSettledInSharesOfCommonStockInLieuOfCash
210000
icu Board Compensation Settled In Shares Of Common Stock In Lieu Of Cash
BoardCompensationSettledInSharesOfCommonStockInLieuOfCash
0
icu Issuance Of Convertible Note Warrant
IssuanceOfConvertibleNoteWarrant
586000
icu Issuance Of Convertible Note Warrant
IssuanceOfConvertibleNoteWarrant
2705000
icu Number Of Enrolled Patients
NumberOfEnrolledPatients
51
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On June 7, 2024, the Company effected a 1-for-25 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock, par value $0.0001 (the "common stock"). Following the effect of the Reverse Stock Split, each 25 shares of the Company’s common stock that were issued and outstanding automatically converted into one outstanding share of common stock
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16788000000
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.5
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-4500000
us-gaap Profit Loss
ProfitLoss
-20400000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135100000
CY2024Q3 us-gaap Cash
Cash
2100000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period. Significant estimates include (i) revenue recognition, (ii) the valuation of the liability classified warrants, (iii) prepaid forward purchase agreement derivative liability, (iv) provision for income taxes, (v) convertible debt measured at fair value, and (vi) the amount of stock-based compensation expense. Although actual results could differ from those estimates, such estimates are developed based on the best information available to management and management's best judgments at the time.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">insured </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limits. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.</span></p>
CY2024Q3 us-gaap Inventory Net
InventoryNet
0
CY2024Q3 icu Inventory Utilized
InventoryUtilized
0
icu Inventory Utilized
InventoryUtilized
0
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
100000
icu Contract With Customer Liability Consideration Received
ContractWithCustomerLiabilityConsiderationReceived
450000
icu Contract With Customer Liability Consideration Received
ContractWithCustomerLiabilityConsiderationReceived
100000
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
550000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
100000
CY2024Q3 icu Sale Of Pediatric Scds
SaleOfPediatricScds
100000
icu Increase In Trade Accounts Receivable Gross
IncreaseInTradeAccountsReceivableGross
68000
icu Increase In Trade Accounts Receivable Net
IncreaseInTradeAccountsReceivableNet
68000
CY2024Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
68000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
68000
CY2024Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1184000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
501000
CY2024Q3 icu Accrued Director Compensation Current
AccruedDirectorCompensationCurrent
296000
CY2023Q4 icu Accrued Director Compensation Current
AccruedDirectorCompensationCurrent
427000
CY2024Q3 icu Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
281000
CY2023Q4 icu Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
507000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
42000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
43000
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
19000
CY2024Q3 icu Accrued Contract Settlement Contingent Liability Current
AccruedContractSettlementContingentLiabilityCurrent
350000
CY2023Q4 icu Accrued Contract Settlement Contingent Liability Current
AccruedContractSettlementContingentLiabilityCurrent
0
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
138000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
26000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2291000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1523000
us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
The Company paid the remaining two monthly installments of principal and interest with the last payment being made in August 2024
us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
two monthly
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
4373000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1087000
icu Gain Loss On Conversion Of Long Term Debt
GainLossOnConversionOfLongTermDebt
-5397000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
10319000
icu Gain Loss On Reporting Period Remeasurement Of Long Term Debt
GainLossOnReportingPeriodRemeasurementOfLongTermDebt
-748000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
700000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
0
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
14
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
5800000
CY2024Q1 icu Loss On Conversion Into Equity
LossOnConversionIntoEquity
4700000
CY2024Q2 icu Suspention Period
SuspentionPeriod
P60D
CY2024Q2 icu Investment Right Notice Period
InvestmentRightNoticePeriod
P10D
CY2024Q2 icu Percentage Of Conversion Amount
PercentageOfConversionAmount
2
CY2024Q2 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
700000
CY2024Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0
CY2024Q3 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0
CY2023Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
95300000
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2359824000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
928209000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
484000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
675000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1544000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
8000
us-gaap Operating Lease Expense
OperatingLeaseExpense
8000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
24000
us-gaap Operating Lease Expense
OperatingLeaseExpense
24000
CY2023Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
200000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4478000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7232000
us-gaap Net Income Loss
NetIncomeLoss
-20411000
us-gaap Net Income Loss
NetIncomeLoss
-16775000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4086871
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4086871
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
801939
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
801939
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3348490
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3348490
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
641125
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
641125
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.1
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.1
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.1
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-26.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-26.16
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2420483
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1003984
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-126498-index-headers.html Edgar Link pending
0000950170-24-126498-index.html Edgar Link pending
0000950170-24-126498.txt Edgar Link pending
0000950170-24-126498-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
icu-20240930.htm Edgar Link pending
icu-20240930.xsd Edgar Link pending
icu-ex31_1.htm Edgar Link pending
icu-ex31_2.htm Edgar Link pending
icu-ex32_1.htm Edgar Link pending
icu-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
icu-20240930_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable